Neurovalens is a global health-tech company focused on developing non-invasive neurostimulation products to solve some of the world’s most significant health challenges. The company’s Modius technology is FDA-cleared, non-invasive, and influences the deep parts of the brain with a small and safe electrical pulse. The noninvasive approach removes the need for surgical implantation and allows much earlier intervention in the treatment pathway.
Neurovalens is currently working to release several versions of the technology to treat various disorders. Modius Sleep is the first product to be released in October of 2024. The Neurovalens headquarters is in Belfast, United Kingdom.
Product Line:
● Modius Sleep (released October 2024)
● Modius Calm (release date TBD)
● Ongoing clinical trial research is currently taking place for additional products designed to treat PTSD, diabetes, and depression.
About Modius Sleep
Modius Sleep is a non-invasive, non-drug, physician-prescribed medical device that can help improve sleep for patients with chronic insomnia. Worn as a headset for 30 minutes each evening, it stimulates sleep neurons deep in the brain by using electrical vestibular nerve stimulation (VeNS), which is a non-invasive therapeutic method. The device sends a safe electrical pulse into the vestibular nerve, influencing the areas of the hypothalamus and brainstem that control circadian rhythm and sleep patterns. The neurostimulation is delivered through two self-adhesive electrode pads, which are placed on the skin behind each ear.
-
Industry
-
Medical Equipment Manufacturing
-
Company size
-
11-50 employees
-
Headquarters
-
Belfast
-
Type
-
Privately Held
-
Founded
-
2013
-
Specialties
-
Neurostimulation, Neuroendocrine, Hypothalamus, health, technology, Sleep, Stress, and Type 2 Diabetes
